Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)

Guardant Health, Inc.

2025-FY EPS reported -$3.32 revenue$982,021,000

Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).
Shield screening tests surged to ~38,000 in Q4 (vs 6,400 prior year).
Preliminary free cash flow: -$54M Q4, -$233M full year.
Cash and marketable securities ~$1.3B as of Dec 31, 2025.
Results are preliminary and unaudited; final audited results expected Feb 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.